Tocagen (TOCA) Posts Earnings Results, Beats Estimates By $0.22 EPS

Tocagen (NASDAQ:TOCA) released its quarterly earnings results on Thursday. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.22, Morningstar.com reports. Tocagen had a negative return on equity of 77.46% and a negative net margin of 130,944.75%. The firm had revenue of $18.01 million for the quarter, compared to analyst estimates of $2.01 million.

TOCA traded up $0.78 during trading on Friday, reaching $13.08. The company’s stock had a trading volume of 184,495 shares, compared to its average volume of 165,769. Tocagen has a 52-week low of $7.52 and a 52-week high of $15.80. The firm has a market capitalization of $240.61 million, a PE ratio of -4.92 and a beta of 2.84. The company has a current ratio of 6.06, a quick ratio of 6.06 and a debt-to-equity ratio of 0.56.

A number of brokerages have weighed in on TOCA. Zacks Investment Research raised Tocagen from a “sell” rating to a “hold” rating in a report on Saturday. ValuEngine raised Tocagen from a “hold” rating to a “buy” rating in a report on Friday, November 2nd. BidaskClub lowered Tocagen from a “buy” rating to a “hold” rating in a report on Friday, October 5th. B. Riley lifted their price objective on Tocagen from $15.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, September 20th. Finally, Chardan Capital began coverage on Tocagen in a report on Thursday, August 30th. They issued a “buy” rating and a $30.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Tocagen currently has an average rating of “Buy” and a consensus price target of $20.75.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its position in shares of Tocagen by 107.4% during the 1st quarter. Russell Investments Group Ltd. now owns 81,067 shares of the company’s stock valued at $961,000 after acquiring an additional 41,978 shares during the period. Millennium Management LLC acquired a new stake in shares of Tocagen during the 1st quarter valued at approximately $402,000. BlackRock Inc. lifted its position in shares of Tocagen by 5.8% during the 2nd quarter. BlackRock Inc. now owns 1,128,767 shares of the company’s stock valued at $10,542,000 after acquiring an additional 62,351 shares during the period. Raymond James & Associates acquired a new stake in shares of Tocagen during the 2nd quarter valued at approximately $142,000. Finally, First Republic Investment Management Inc. acquired a new stake in shares of Tocagen during the 2nd quarter valued at approximately $170,000. 28.00% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Tocagen (TOCA) Posts Earnings Results, Beats Estimates By $0.22 EPS” was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of US & international copyright laws. The correct version of this piece of content can be viewed at https://www.wkrb13.com/2018/11/10/tocagen-toca-posts-earnings-results-beats-estimates-by-0-22-eps.html.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Further Reading: Return on Investment (ROI)

Earnings History for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply